X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cabozantinib (457) 457
index medicus (263) 263
oncology (237) 237
humans (201) 201
cancer (127) 127
metastasis (114) 114
male (86) 86
sorafenib (85) 85
everolimus (81) 81
sunitinib (78) 78
c-met (71) 71
antineoplastic agents - therapeutic use (70) 70
vandetanib (70) 70
open-label (69) 69
pharmacology & pharmacy (69) 69
female (68) 68
met (68) 68
targeted therapy (63) 63
renal cell carcinoma (61) 61
angiogenesis (59) 59
care and treatment (58) 58
double-blind (56) 56
thyroid cancer (56) 56
middle aged (55) 55
animals (54) 54
carcinoma (51) 51
nivolumab (50) 50
protein kinase inhibitors - therapeutic use (50) 50
tyrosine kinase inhibitor (49) 49
tyrosine (48) 48
analysis (47) 47
chemotherapy (47) 47
inhibitor (47) 47
vascular endothelial growth factor (47) 47
pyridines - therapeutic use (46) 46
survival (46) 46
anilides - therapeutic use (44) 44
endothelial growth-factor (44) 44
expression (44) 44
prostate cancer (43) 43
therapy (43) 43
treatment outcome (43) 43
aged (42) 42
tumors (42) 42
patients (40) 40
article (39) 39
research (39) 39
axitinib (38) 38
medicine & public health (38) 38
cancer therapies (37) 37
carcinoma, renal cell (37) 37
carcinoma, renal cell - drug therapy (37) 37
drug therapy (37) 37
renal-cell carcinoma (37) 37
tyrosine kinase inhibitors (37) 37
clinical trials (36) 36
immunotherapy (36) 36
kinases (36) 36
adult (35) 35
kidney cancer (35) 35
medullary-thyroid cancer (35) 35
xl184 (35) 35
review (34) 34
antineoplastic agents - pharmacology (33) 33
medical prognosis (33) 33
metastases (33) 33
mutation (33) 33
trial (33) 33
kidney neoplasms - drug therapy (32) 32
phase-ii (32) 32
urology & nephrology (32) 32
lenvatinib (31) 31
mutations (31) 31
pazopanib (31) 31
ret (31) 31
interferon-alpha (30) 30
pyridines - pharmacology (30) 30
thyroid neoplasms - drug therapy (30) 30
health aspects (29) 29
phase-ii trial (29) 29
anilides - pharmacology (27) 27
cell lung-cancer (27) 27
growth (27) 27
medullary thyroid cancer (27) 27
protein kinase inhibitors - pharmacology (27) 27
resistance (27) 27
cell line, tumor (26) 26
pharmacokinetics (26) 26
antineoplastic agents - adverse effects (25) 25
disease-free survival (25) 25
hepatocellular carcinoma (25) 25
molecular targeted therapy (24) 24
neoplasm metastasis (24) 24
proto-oncogene proteins c-ret - genetics (24) 24
pyridines - administration & dosage (24) 24
antineoplastic agents - administration & dosage (23) 23
mice (23) 23
neoplasms. tumors. oncology. including cancer and carcinogens (23) 23
anilides - administration & dosage (22) 22
antineoplastic agents (22) 22
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 03/2016, Volume 374, Issue 9, pp. 889 - 890
Journal Article
Cancer Discovery, ISSN 2159-8274, 12/2018, Volume 8, Issue 12, pp. 1529 - 1539
We present a cohort of 41 patients with osimertinib resistance biopsies, including 2 with an acquired CCDC6-RET fusion. Although RET fusions have been... 
LUNG-CANCER | CABOZANTINIB | TKI | ONCOLOGY | MUTATION | ERLOTINIB | AZD9291
Journal Article
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, ISSN 0027-8874, 06/2019, Volume 111, Issue 6, pp. 575 - 583
Background Liquid biopsy for plasma circulating tumor DNA (ctDNA) next-generation sequencing (NGS) is commercially available and increasingly adopted in... 
CABOZANTINIB | OPEN-LABEL | PHASE-2 | ONCOLOGY | ADENOCARCINOMAS | CELL-FREE DNA
Journal Article
Oncogene, ISSN 0950-9232, 05/2016, Volume 35, Issue 21, pp. 2687 - 2697
Antiangiogenic therapy resistance occurs frequently in patients with metastatic renal cell carcinoma (RCC). The purpose of this study was to understand the... 
ACTIVATION | METASTASIS | ANGIOGENESIS | BIOCHEMISTRY & MOLECULAR BIOLOGY | CANCER | CELL BIOLOGY | RECEPTOR TYROSINE KINASES | CABOZANTINIB XL184 | ONCOLOGY | C-MET | GROWTH | GENETICS & HEREDITY | EXPRESSION | PROGRESSION | Proto-Oncogene Proteins c-met - metabolism | Humans | Drug Resistance, Neoplasm | Molecular Targeted Therapy | Sunitinib | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Carcinoma, Renal Cell - enzymology | Indoles - pharmacology | Carcinoma, Renal Cell - drug therapy | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | Signal Transduction | Carcinoma, Renal Cell - pathology | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Angiogenesis Inhibitors - pharmacology | Proto-Oncogene Proteins - genetics | Receptor Protein-Tyrosine Kinases - metabolism | Proto-Oncogene Proteins c-met - genetics | Xenograft Model Antitumor Assays | Pyrroles - pharmacology | Animals | Receptor Protein-Tyrosine Kinases - genetics | Mice, Nude | Kidney Neoplasms - enzymology | Kidney Neoplasms - pathology | Cell Proliferation - drug effects | Mice | Kidney Neoplasms - drug therapy | Molecular targeted therapy | Genetic aspects | Carcinoma, Renal cell | Drug therapy | Drug resistance | Properties | Phosphotransferases | Methods | Cancer therapies | Kidney cancer | Metastasis | Cabozantinib | Renal Cell Carcinoma | AXL | MET
Journal Article
ONKOLOGE, ISSN 0947-8965, 03/2017, Volume 23, Issue 3, pp. 232 - 233
Journal Article
Biomedical Chromatography, ISSN 0269-3879, 07/2018, Volume 32, Issue 7, pp. e4227 - n/a
Cabozantinib (CBZ) is used for the treatment of progressive, metastatic medullary thyroid cancer. Its major oxidative metabolite is cabozantinib N‐oxide (CBN),... 
pharmacokinetics | cabozantinib N‐oxide | plasma | LC–MS/MS | cabozantinib | cabozantinib N-oxide | CHEMISTRY, ANALYTICAL | EVEROLIMUS | VOLUNTEERS | BIOCHEMISTRY & MOLECULAR BIOLOGY | BIOCHEMICAL RESEARCH METHODS | OPEN-LABEL | RENAL-CELL CARCINOMA | LC-MS | DOSE PROPORTIONALITY | PHARMACOLOGY & PHARMACY | Thyroid cancer | Metabolites | Mass spectrometry | Methods | Index Medicus
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 01/2018, Volume 24, Issue 1, pp. 204 - 213
Purpose: Efforts to discover drugs that overcome resistance to targeted therapies in patients with rare oncogenic alterations, such as NTRK1 and ROS1... 
CABOZANTINIB | ONCOGENE | ONCOLOGY | CRIZOTINIB RESISTANCE | INHIBITOR | PROTEINS | CHEMOTHERAPY
Journal Article
Thyroid, ISSN 1050-7256, 06/2019, Volume 29, Issue 6, pp. 83 - 844
Background: Medullary thyroid carcinoma (MTC) presents a disproportionate number of thyroid cancer deaths due to limited treatment options beyond surgery.... 
Thyroid Cancer and Nodules | microRNAs | tyrosine kinase inhibitors | tumor suppressors | cabozantinib resistance | targeted intravenous delivery | nanocells | MIGRATION | CABOZANTINIB | PROLIFERATION | TARGETING SNAI1 | CELL LUNG-CANCER | INVASION | GASTRIC-CANCER | PATHWAY | ENDOCRINOLOGY & METABOLISM | TUMOR-SUPPRESSOR | NODAL METASTASIS
Journal Article
Bulletin du Cancer, ISSN 0007-4551, 06/2015, Volume 102, Issue 6, pp. 501 - 508
Therapeutic arsenal in prostate cancer widens for several years. New hormonal therapies such as acetate abiraterone or enzalutamide were the first molecules to... 
Cabozantinib | Abiraterone | MOSCATO | Enzalutamide | CRPC
Journal Article
Cancer Discovery, ISSN 2159-8274, 07/2018, Volume 8, Issue 7, pp. 836 - 849
The receptor tyrosine kinase rearranged during transfection (RET) is an oncogenic driver activated in multiple cancers, including non-small cell lung cancer... 
CELL LUNG-CANCER | TYROSINE KINASE INHIBITORS | CABOZANTINIB | ONCOLOGY | ADENOCARCINOMA | CRIZOTINIB | RESISTANCE | OPEN-LABEL | FUSIONS | CHEMOTHERAPY | CHRONIC MYELOID-LEUKEMIA
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 01/2017, Volume 23, Issue 1, pp. 204 - 213
Purpose: Efforts to discover drugs that overcome resistance to targeted therapies in patients with rare oncogenic alterations, such as NTRK1 and ROS1... 
CABOZANTINIB | ONCOGENE | ONCOLOGY | CRIZOTINIB RESISTANCE | INHIBITOR | REARRANGEMENTS | PROTEINS | ROS1 | CHEMOTHERAPY
Journal Article
BLOOD, ISSN 0006-4971, 07/2019, Volume 134, Issue 1, pp. 30 - 43
The era of targeted therapies has seen significant improvements in depth of response, progression-free survival, and overall survival for patients with... 
MULTIPLE-MYELOMA | TYROSINE KINASE AXL | CABOZANTINIB | TECHNOLOGIES | INHIBITION | GENE | BONE METASTASIS | PROLIFERATION | HEMATOLOGY | EXPRESSION | SOFTWARE
Journal Article
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 08/2019, Volume 25, Issue 16, pp. 4924 - 4932
Purpose: Aberrant activation of MET (hepatocyte growth factor receptor) signaling is implicated in the tumorigenesis of human cancers. This phase I study... 
TRIAL | CABOZANTINIB | AMPLIFICATION | ONCOLOGY | GROWTH | CRIZOTINIB | RESISTANCE | SUNITINIB | VOLITINIB | RENAL-CELL CARCINOMA | DISCOVERY | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2018, Volume 36, Issue 36, pp. 3529 - 3532
Journal Article
American Journal of Surgical Pathology, ISSN 0147-5185, 08/2018, Volume 42, Issue 8, pp. 1121 - 1126
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 04/2019, Volume 111, Issue 4, pp. 388 - 398
Breast cancer brain metastases (BrMs) are defined by complex adaptations to both adjuvant treatment regimens and the brain microenvironment. Consequences of... 
RET | CABOZANTINIB | INHIBITION | EVOLUTION | CANCER CELLS | ONCOLOGY | LANDSCAPE | RESISTANCE | LAPATINIB PLUS CAPECITABINE | XENOGRAFTS | REVEALS
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.